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Abstract
Until recently many studies of bone remodeling at the cellular level have focused on the behavior of mature
osteoblasts and osteoclasts, and their respective precursor cells, with the role of osteocytes and bone lining
cells left largely unexplored. This is particularly true with respect to the mathematical modeling of bone
remodeling. However, there is increasing evidence that osteocytes play important roles in the cycle of
targeted bone remodeling, in serving as a significant source of RANKL to support osteoclastogenesis,
and in secreting the bone formation inhibitor sclerostin. Moreover, there is also increasing interest in
sclerostin, an osteocyte-secreted bone formation inhibitor, and its role in regulating local response to
changes in the bone microenvironment.
Here we develop a cell population model of bone remodeling that includes the role of osteocytes,
sclerostin, and allows for the possibility of RANKL expression by osteocyte cell populations. We have
aimed to give a simple, yet still tractable, model that remains faithful to the underlying system based on
the known literature. This model extends and complements many of the existing mathematical models
for bone remodeling, but can be used to explore aspects of the process of bone remodeling that were
previously beyond the scope of prior modeling work. Through numerical simulations we demonstrate
that our model can be used to explore theoretically many of the qualitative features of the role of
osteocytes in bone biology as presented in recent literature.
Introduction
The skeleton is a highly dynamic organ that undergoes constant remodeling throughout life. Remodeling
is involved in systemic mineral homeostasis and is required for the routine repair of microfractures and for
adaptation to mechanical stress. Even after the skeleton reaches its adult size, bone remains metabolically
active. Bone remodeling involves the coupling of bone resorption and bone formation, and diseases are
characterized by imbalances between formation and resorption. This includes such common disorders
as osteopenia and osteoporosis [1], as well as malignant processes such as multiple myeloma and other
cancers that metastasize to the bone [2, 3]. As these disorders contribute to morbidity and mortality in
millions of people worldwide, there is great interest in improving our understanding the processes that
regulate bone remodeling.
Bone remodeling is characterized by complex mechanical and biochemical signaling pathways. Remod-
eling typically occurs for one of three reasons: to maintain mineral homeostasis; to adapt to mechanical
changes; and to repair damage [4, 5]. Remodeling related to mineral homeostasis need not occur at a
specific site, and is therefore referred to as non-targeted remodeling [4,5]. In contrast, remodeling due to
mechanical changes or to damage is site-specific and is termed targeted remodeling [4,5]. The key cellu-
lar players in targeted bone remodeling include the osteoblasts and osteoclasts. There is also increasing
evidence to support the role of osteocytes as active participants in this remodeling process [6, 7].
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2Osteocytes are mature osteoblasts that become embedded within the bone matrix during the for-
mation phase of bone remodeling. During this process osteocytes develop cytoplasmic processes which
run through the canaliculi, forming a communication network that can convert mechanical signals into
biochemical signals [6–8]. Osteocytes are the most abundant and long-living bone cells and are found
throughout the skeleton, in contrast to the much shorter lived osteoblasts and osteoclasts which are only
transiently found on the surface of the bone. Osteocytes actively secrete growth factors that stimulate
bone formation, as well as sclerostin, which inhibits bone formation [7–9]. The complex relationship
between osteocytes, osteoblasts, osteoclasts, and their precursors, is continuing to be elucidated.
A number of mathematical and computational models of various aspects of bone physiology have been
proposed. Many of these models focus on either bone fracture healing, [5, 10–14], or bone remodeling,
[1,15–31]. These models take different approaches, and focus on various aspects of the remodeling process.
The early modeling approach described in [21,22] makes use of the biochemical systems analysis formalism
of Savageau (e.g., [32–36]) developed to represent bone remodeling as the effect of changes in bone cell
populations; a so-called “cell population” model. These models are comprised of a system of two ordinary
differential equations (ODEs) representing the cell population dynamics of osteoclasts and osteoblasts.
In addition, they are chemically implicit in that they do not track chemical quantities as functions of
time or location, but instead incorporate the biochemical mechanisms in an abstract way. Furthermore,
these models do not attempt to represent biomechanical mechanisms of remodeling. Instead, the authors
relate remodeling cell populations to the change in bone mass, or bone volume, thus allowing a way
to track the physical effects of resorption and formation. This approach was used in [37] to model
osteomyelitis. Others, e.g., [25,26], have modeled only the resorption phase of remodeling. These models
do not track remodeling cell populations, but rather cellular activity represented by enzyme reaction
equations. All of these models, as well as most others, incorporate the actions of the most prominent
signaling pathways involved in bone remodeling, as well as various other autocrine and paracrine signaling
pathways depending on the specific considerations.
The models presented in [16,18,28,29] are also cell population models that describe bone remodeling
cell dynamics as controlled by autocrine and paracrine signaling. These models use a biochemically
explicit approach, in that the model equations contain terms corresponding to interactions of remodeling
cells with specific cytokines. Another distinction is that while the models represented in [21, 22, 25, 26]
represent remodeling on the scale of an individual basic multicellular unit (BMU), the models in [17,23,
27,28] average over a volume of bone. By a BMU we mean a localized collective of bone cells working as
an organized unit to carry out a single, complete cycle of the remodeling process, see e.g., [38]. We note
that the models found in [1, 5, 6, 18, 44, 45] consider remodeling of individual BMUs, but in a spatially
explicit context, which is beyond the scope of this paper. However, the model developed herein can be
easily modified to obtain a spatially explicit model.
The complexity of the skeletal system and its interactions with the rest of the body limits the ability
of a single model to capture all of the relevant biological, biochemical, and biophysical mechanisms
of remodeling on all scales simultaneously. Moreover, parameterization of a given model is difficult,
given the dependency on accuracy and availability of data. Here we introduce a novel mathematical
model for bone remodeling that maintains those fundamental mechanisms captured in previous models,
while incorporating biological aspects of bone remodeling that have not previously been considered. In
particular, this model includes osteocytes, their biochemical processes, and their interactions with other
bone remodeling cells, and thus represents a significant advance to the field.
3Materials and Methods
Mathematical Modeling
In developing a new mathematical model for bone remodeling we have chosen to employ the biochemical
systems analysis formalism used in e.g. [1, 15, 20–22, 30], but extended to incorporate further biological
detail. We chose this approach in anticipation of the type of data to which we may eventually have
access, and the types of questions which are of concern to us. For example, explicit chemical data
are not obtained in current clinical practice. Our approach does represent many of the mechanisms
contained in [17, 23, 28, 29], albeit implicitly. In particular, we incorporate the actions of an important
signaling pathway based on the specific molecules: receptor activator of nuclear factor κ-B (RANK); and
osteoprotegerin (OPG) [2,3,39–42]. These cytokines, plus the RANK ligand, form a pathway commonly
known as the RANK/RANKL/OPG pathway. We also incorporate the actions of growth factors such as
transforming growth factor β (TGF-β) [43, 44], and other cytokines on bone remodeling cells. It is well
known that RANKL is a key cytokine in the differentiation process of osteoclast cells, while OPG, which
is produced by differentiated osteoblastic cells, has been shown to function as an inhibitory factor for
osteoclastogenesis [38].
We have developed a cell population model for osteocyte-induced targeted bone remodeling. This
model consists of the osteocyte, pre-osteoblast, osteoblast, and osteoclast cell populations; the interactions
of these cells with one another, and through the power law formalism the autocrine and paracrine signaling
among these cells. Figure 2 shows the equations that make up the model, these are described in detail
below. In this model we explicitly include the population of pre-osteoblasts to emphasize the switch of
cells in the osteoblast lineage from being osteoclastogenic, i.e., osteoclast generating, to being osteogenic,
i.e., bone forming, see e.g., [45,46]. Specifically, there is a clear distinction between the signaling behaviors
of pre-osteoblasts and osteoblasts that is important for the considerations taken up in this work. On the
other hand, for the purposes we have in mind there is no similar a priori reason to explicitly represent a
population of pre-osteoclasts.
A general assumption is that there is a large pool of mesenchymal stem cells available to differentiate
into pre-osteoblasts [28]. Similarly, we assume there is a large pool of osteoclast progenitor cells which are
available to differentiate to fully committed mature osteoclasts [28]. Such cell differentiation is determined
by autocrine and paracrine signaling discussed in more detail below, see also [8]. We assume that some
percentage of pre-osteoblasts differentiate under the influence of autocrine and paracrine signaling while
some percentage undergo apoptosis. We also assume that some percentage of mature osteoblasts will
undergo apoptosis, and some percentage of osteoblasts will become embedded in the bone matrix as
osteocytes . Figure 1 outlines the assumptions that we make to construct the mathematical model. The
details of the assumptions and how they influence the development of a mathematical model is described
in detail below.
In the following we denote by S(t), or simply S, the osteocyte cell population at given time t. Sclerostin
is produced by osteocytes and inhibits the Wnt/β-catenin pathway, [6, 8]. Wnt is known to promote
osteoblastic proliferation and differentiation [7]. We incorporate the effects of sclerostin and the Wnt/β-
catenin pathway into the mathematical model through a term of the form
(
1− SKS
)
+
, where (x)+ =
max(x, 0), and KS is a parameter that describes the relation between osteocyte apoptosis and decrease in
sclerostin inhibition. The idea is that, for a threshold level KS of osteocytes, there is sufficient sclerostin
production to inhibit local Wnt signaling. When osteocytes die, the sclerostin level decreases, [6, 8].
This releases osteoblast precursor cells from Wnt inhibition, thereby initiating a cycle of targeted bone
remodeling. We note that the term
(
1− SKS
)
+
is a dimensionless quantity that is used to modify the
standard biochemical systems analysis formalism in order to accurately capture the action of sclerostin
signaling as previously described. It is also important to note that in the biochemical systems analysis
formalism the basic relations used to represent signaling are nonlinear. However, it may be the case that
4the exponents used take on numerical values equal or close to unity. This should not be misconstrued as
an a priori assumption of linearity within the model.
Equation (1) in Figure 2 describes the dynamics of the osteocyte cell population. This equation
simply states that osteocytes are mature osteoblasts that become embedded in extra cellular matrix
at a given rate α1. We further note that there is no death term for osteocytes in equation (1). This
is due to our assumption that, over the time scale of a single event of targeted remodeling considered
here, the most significant influence on osteocyte apoptosis is the initial biomechanical action that begins
remodeling [9, 47]. This appears in the mathematical model as an initial condition.
The pre-osteoblast cell population at a time t is denoted by P (t), or simply P . Pre-osteoblasts are
differentiated mesenchymal stem cells. We assume that this differentiation is controlled by osteocytes
through the sclerostin, Wnt/β-catenin pathways, and various growth factors. The effectiveness of scle-
rostin regulations of the differentiation of mesenchymal stem cells to become pre-osteolbasts is represented
mathematically by
(
1− SKS
)g22
+
. Where g22 is a dimensionless parameter. Thus when osteocytes undergo
apoptosis due to microdamage, local mesenchymal stem cells differentiate to pre-osteoblasts due to the
resulting signaling. Moreover, the pre-osteoblasts are free to proliferate and differentiate to mature os-
teoblasts since they have been released from Wnt inhibition. Equation (2) in Figure 2 describes the
dynamics of the pre-osteoblast cell population. This equation states that pre-osteoblasts are differenti-
ated from a large pool of stem cells at a rate α2 in response to signaling molecules produced by osteocytes,
that pre-osteoblasts proliferate at a rate α3 under the influence of autocrine signaling provided this is
not inhibited by sclerostin. Furthermore, pre-osteoblasts differentiate to become mature osteoblasts at
a rate β1. This is under the influence of autocrine and osteoclast regulated paracrine signaling. Finally,
pre-osteoblasts undergo apoptosis at a rate δ.
The osteoblast cell population at a time t is denoted by B(t), or simply B. Equation (3) in Figure
2 describes the dynamics of the mature osteoblast cell population. This equation states that osteoblasts
are differentiated pre-osteoblasts, that osteoblasts undergo apoptosis, and that some osteoblasts are
embedded in the extra cellular matrix during formation to become osteocytes. Notice that the term
α1B
g31
(
1− SKS
)
+
also appears in equation (1) of Figure 2, representing the embedding of osteoblasts
that become osteocytes, and the term β1P
f12Cf14 , also appears in equation (2) of Figure 2, which
corresponds to the differentiation of pre-osteoblasts to become mature osteoblasts. Here the parameter
f12 describes the pre-osteoblast autocrine signaling. The parameter f14 represents the effects of osteoclast
derived paracrine signaling on pre-osteoblasts. This could represent, for example, the effects of TGF-β
on pre-osteoblasts as described for example in [28].
The osteoclast cell population at a time t is denoted by C(t), or simply C. The equation (4) in Figure
2 describes the dynamics of the osteoclast cell population. This equation states that mature osteoclasts
come from the differentiation of a large pool pre-osteoclasts at a rate α4. This differentiation is influ-
enced essentially by the RANK/RANKL/OPG pathway. Thus the term Sg41P g42(ε+B)
g43
(
1− SKS
)g44
+
,
describes the effects of this pathway. The dimensionless parameter g44 models the effectiveness of scle-
rostin regulation of osteoclastogensis. One novel feature of this model is that we have included osteocytes
as a source of RANKL as discussed in recent literature [6–9, 48]. The parameter g41 represents the ef-
fect of osteocyte derived RANKL signaling on osteoclastogenesis. We also retain pre-osteoblast derived
RANKL signaling via the parameter g42. While we have explicitly included the pre-osteoblast cell pop-
ulation dynamics, we have neglected to explicitly include a dynamic cell population for pre-osteoclasts.
This is based on a simplifying assumption that, over the relevant time span, there is a steady pool of
circulating pre-osteocalsts that may be recruited for differentiation to active osteoclasts. This simplifying
assumption is common the literature on mathematical modeling of bone remodeling, e.g., [15–18,21–23].
We note that either of these, g41 or g42, could take on the value 0. Thus advances in the understanding
of the relative role of osteoblasts and osteocytes in RANKL production would result in parameter changes
in our model, but not a change in the model structure itself.
5The term (ε+B)
g43 represents the effect of OPG acting as a decoy receptor for RANKL. Typically the
parameter g43 takes on negative values, and since B has 0 as a steady state value, we add a sufficiently
small number ε to avoid dividing by zero. This represents the factor of production when B= 0. We also
have a term for the osteoclast cell death at a rate β3.
We denote by z(t), or simply z, the bone mass at a given time t. We follow [22, 28] to develop an
equation for the change of bone mass (or bone volume depending on the scaling) over time. The rate of
change of bone mass has the form
dz
dt
= formation - resorption.
As in e.g., [28], we assume that the amount of bone being resorbed is proportional to the osteoclast
population, while the amount of bone being formed is proportional to the osteoblast population.
We can summarize the mathematical model with the following verbal description:
1. change in osteocytes = increase due to embedded osteoblasts
2. change in pre-osteoblasts = increase due to differentiation of stromal cells (released from scle-
rostin or exposure to growth factors) + proliferation of pre-osteoblasts (autocrine signaling of Wnt
and growth factors) – differentiation to osteoblasts (growth factors) - apoptosis
3. change in osteoblasts = increase due to differentiation of pre-osteoblasts (growth factors) –
apoptosis – embedding as osteocytes
4. change in osteoclasts = increase due to differentiation of pre-osteoclasts (due to RANKL and
limited by OPG) - apoptosis
5. change in bone mass = increase due to activity of osteoblasts – activity of osteoclasts
The corresponding full mathematical model is the set of equations shown in Figure 2. The definitions
of the variables and parameters appearing in the model equations of Figure 2 is summarized in table 1.
Initial Conditions
The initial conditions for the mathematical model are given by S(0) = KS − ρ, where ρ > 0 is a constant
that represents osteocyte apoptosis, which corresponds to a drop in sclerostin levels, P (0) = B(0) =
C(0) = 0, and z(0) = 100. Observe that the system of model equations (1)-(4) has as a steady state,
the values Sss = KS , Pss = 0, Bss = 0, and Css = 0. The significance being that this steady state
allows one to model the initiation of an event of targeted bone remodeling. In particular, our model does
not assume the presence of a population of committed pre-osteoblasts or active osteoclasts in order to
begin a remodeling cycle. This is in contrast with previously published mathematical models of bone
remodeling which require either a population of active osteoclasts, or a population of pre-osteoblasts
to initiate dynamics corresponding to physiological bone remodeling. However, it should be noted that
physiological bone remodeling also involves the movement of bone lining cells away from the bone surface.
This aspect of bone remodeling is complicated and not yet fully understood. The steady state value for
bone volume, denoted zss depends significantly on the parameter values. For instance, if the parameter
values are such that there is an imbalance of osteoblasts and osteoclasts, in favor of osteoblasts, then
there will be over remodeling.
6Numerical Simulations
The mathematical model is a system of coupled nonlinear ordinary differential equations (ODEs). To use
the mathematical model to simulate bone remodeling we must solve this system along with the specified
initial conditions. In order to do so we use the MATLAB software for scientific computing. In particular,
we use the MATLAB ODE suite [49], and the program ode23s to integrate the problem (1)-(5) with the
above initial conditions. For a further discussion of the numerical techniques underlying the codes in the
MATLAB ODE suite see [50,51].
Parameters
Table 2 lists the values of the parameters in the model equations (1)-(5) that we have taken as base-
line values. These particular values are chosen so that a cycle of normal, targeted bone remodeling is
completed, i.e., bone cell populations reach a steady state value, after approximately one hundred days.
Results
Baseline Case
Figure 3 shows the simulation results for bone cell populations during a single cycle of normal targeted
bone remodeling. Here, normal targeted bone remodeling is defined to be a complete remodeling cycle
that takes place over a period of one hundred days, in which the amount of new bone formed is equal
to the amount of old or damaged bone resorbed. One characteristic of normal bone remodeling that
manifests itself quantitatively is that the steady state value of bone volume, here and below denoted by
zss, is equal to one hundred percent. The simulations shown in Figure 3 result from solving the model
equations (1)-(5) with the above initial conditions, and parameter values shown in table 2. Figure 3(a)
shows the dynamics of the osteocyte cell population during an event of targeted bone remodeling. Initially
there is a decrease from the steady state value KS in the osteocyte cell population. This corresponds to
local osteocyte apoptosis, and results in a decrease in local sclerostin levels. This releases stromal cells
from sclerostin inhibition, allows for Wnt signalling, and results in proliferation and differentiation of pre-
osteoblast cells, Figure 3(b). There follows an increase in osteoblast cell number due to differentiation of
pre-osteoblasts, and differentiation of osteoclast pre-cursors to mature osteoclasts, Figure 3(c) and Figure
3(d). Remodeling ceases once the local osteocyte cell population is replenished, and the osteocyte cell
network is reestablished, returning sclerostin expression back to sufficient levels thereby inhibiting bone
turnover.
Figure 4 shows the dynamics of bone volume during a single event of targeted bone remodeling. An
increase in the osteoclast cell numbers results in bone resorption and the decrease in bone volume, while
increases in osteoblast cell number results in bone formation. In this case bone turnover is completely
balanced in the sense that the amount of new bone formed equals the amount resorbed. Mathematically
this corresponds to a steady state value of bone mass, zss= 100%.
Role of Osteocyte RANKL Production
At the scale of a BMU, bone cells are easily affected by changes in the microenvironment. Thus we
expect that small changes in the model parameter values could significantly impact bone turnover during
remodeling. In this section we study the influence of expression of RANKL by osteocytes on targeted bone
remodeling. In particular, we are interested in the question of whether local RANKL expression by pre-
osteoblasts, or by osteocytes has the greater impact. Following [28], we take as a control parameter the
change in bone volume. This provides a measurable quantity by which we can assess the reasonableness
7of the mathematical model. If zss> 100 then there is over-remodeling. If zss< 100 then there is under-
remodeling.
That RANKL/OPG expression by cells in the osteoblastic lineage is fundamental for the activation
and control of bone remodeling is by now well established. Until recently, the paradigm was that pre-
osteoblasts serve as the primary source for RANKL and active osteoblasts serve as the primary source of
OPG [46]. More recent research highlights that osteocytes also express RANKL at significant levels, and
have a strong influence on the activation and regulation of remodeling [6–9,48,52]. To explore this we vary
the parameters g41 and g42 in equation (4) over the range from zero to two. These parameters correspond
to the effectiveness of the expression of RANKL by osteocytes, and pre-osteoblasts respectively. By
varying these parameter values simultaneously we gain insight into how RANKL expression by osteocytes
and pre-osteoblasts impacts the regulation of a cycle of targeted bone remodeling. We note that the system
is very sensitive to changes in the effectiveness of RANKL expression. In particular, small perturbations
to the amount of RANKL can lead to pathological remodeling. First we compute zss as a simultaneous
function of g41 and g42, and observe that values of g41 and g42 that are simultaneously large, in this case
> 1, result in physiologically unrealistic over resorption (under remodeling). Next we compute zss as a
function of each of g41 and g42 individually with the other fixed. We observe that it is possible to have
values such that either g41>g42, or g41<g42 and resulting in zss ≈ 100%. Table 3 lists some specific values
of g41, and g42 that result in normal targeted bone remodeling. Thus, given cell population data, this
model can be used, with parameter fitting, to determine whether osteocytes or pre-osteoblasts provide
the dominant RANKL source during targeted bone remodeling. This allows for more thorough testing
of hypotheses such as in [48], which suggests that RANKL produced by osteoblast precursors contribute
little to adult bone remodeling.
Signaling of Osteocytes and Pre-osteoblasts
In this section we explore the behavior of the system as it is affected by changes in the effectiveness of
osteocyte paracrine, and pre-osteoblast autocrine signaling. In particular, we regard how these actions
influence the differentiation of stromal cells into pre-osteoblasts, and the proliferation of pre-osteoblast
cells. These aspects of BMU remodeling are strongly influenced by sclerostin signaling. While previous
mathematical models have included pre-osteoblast proliferation, explicit inclusion of osteocyte signaling,
and the effects sclerostin, has been outside the scope of those works and thus is another feature of novelty
in this work.
We compute the steady state bone volume, zss, as a simultaneous function of the effectiveness of
osteocyte paracrine signaling on stromal cell differentiation, g21, and pre-osteoblast autocrine signaling
for pre-osteoblast proliferation, g32. The results are shown in Figure 5, Figure 6, and Figure 7. The
reason to consider these parameters simultaneously is that these terms both influence the “production”
of pre-osteoblasts in (2). First, we observe that the parameter g21 is considerably more sensitive to
variation than g32, this is seen in Figure 5 and in a comparison between Figure 6 and Figure 7. In the
context of the model, this suggests that the influence of osteocyte signaling, and sclerostin specifically,
on stromal cell differentiation into pre-osteoblasts is key to the model. In fact, we can obtain a steady
state value for bone volume, zss, corresponding to normal bone remodeling for a relatively wide range of
g32 values, provided g21 is at or near baseline value. The significance of the role of osteocyte signaling is
particularly strong with regard to the initiation of a cycle of targeted remodeling, since as pointed out
above, the steady state values for all cell populations, except osteocytes, is zero. That is, we do not have
a presence of cells fully committed to either the osteoblast or osteoclast lineage when there is no active
remodeling. This is a point of departure with previous mathematical models where positive steady state
values of mature osteoblasts and osteoclasts occur.
8Application to Study Anti-sclerostin Drugs
We can apply the model system to study the effects of using an anti-sclerostin drug. Many drugs for
treating bone disease, such as biphosphonates, are designed to inhibit resorption, and to decrease the
loss of bone mass. On the other hand, anti-sclerostin drugs purport to promote bone formation, thereby
increasing bone mass [53, 54]. Sclerostin inhibits Wnt/β-catenin, so anti-sclerostin would promote os-
teoblast differentiation. In addition, Wnt signaling increases OPG expression, which inhibits osteoclasts,
so anti-sclerostin would be expected to increase OPG release too. Sclerostin has been shown to downreg-
ulate OPG and increase levels of RANKL. By modifying the parameters g22 and g44 which represent the
effectiveness of sclerostin regulation of osteoblastogenesis and osteoclastogenesis respectively, albeit in an
abstract manner, we can study the effects of an anti-sclerostin agent on bone remodeling in a situation
where there is known to be an imbalance in resorption/formation (e.g., abnormal osteoclast activity).
To model the inclusion of an anti-sclersotin drug we proceed as follows. In general, the parameters
g22 and g44 now become time dependent, that is g22(t) and g44(t). The form of the time dependence
is determined by the frequency of dosing, the half life of the drug, and potentially the method of drug
delivery. We note that since g22 and g44 are exponents in a power law approximation they must be
dimensionless quantities, this remains the case even when they are made to depend on time. We take the
function g22(t) to be a constant value G22 over a specific time interval t1 to t2, and the baseline value
otherwise. We take the function g44(t) to be a constant G44 over another time interval t3 to t4, and the
baseline value otherwise. The constants G22 an G44 represent the perturbation of the baseline parameter
values for g22 and g44 respectively. In order to get an increase in bone formation we must have G22 be
less than the baseline value, and G44 be greater than the baseline value. The time intervals t1 to t2, and
t3 to t4 represent the period of activity of the given dose of the drug. The time interval t1 to t2 is the
time over which the drug effects Wnt signaling. The time interval t3 to t4 is the time over which the drug
effects OPG signaling. We note that these two time intervals may be the same.
Figure 8 shows the change in bone mass as a function of time in the case of simulated pathological
remodeling. Here we simulate the results of a hypothetical bone disease that results in over resorption.
This is modeled by increasing the value of α4 from its baseline value as listed in table 2 to a value of
α4= 0.11. Figure 8 shows the bone mass as a function of time under conditions where there is over
resorption and no treatment, that is all parameters other than α4 are set to baseline values, and, in
particular we do not yet modify g22 and g44.
Next, we simulate the treatment of the pathological remodeling, such as is show in Figure 8, via an
anti-sclerostin agent. Figure 9 shows the results obtained by including treatment with an anti-sclerostin
drug, implemented by modifying the parameters g22 and g44 as described above. Specifically, all the
parameters are the same as those used to obtain the results show in 8, but now we modify g22 and
g44 to be the functions g22(t) and g44(t), previously defined, to model the effects of treatment with an
anti-sclerostin antibody. We observe a dose dependent increase in bone mass as described in [53,54].
There are several notable features regarding the treatment of bone loss using an anti-sclerostin anti-
body within the context of this model. One is that the time of the dosing matters. The closer to initial
stages of osteoclastogenesis that the dose is given, the better the response of increased bone formation.
This is particularly the case with respect to OPG signaling related parameter g44. Another feature we
observed is that the parameter g22, which corresponds primarily to Wnt signaling, is sensitive to the
perturbations that model dosing with an anti-sclerostin drug. That is, it takes only a small decrease in
the value over a short period of time for a marked increase in bone formation.
Discussion
We have developed a cell population mathematical model in the form of a system of nonlinear ordinary
differential equations for the principal bone cells involved in local targeted bone remodeling. The primary
9goal for this work was to include features of major focus in some of the most recent experimental research
on bone remodeling at the cellular level. In particular we have aimed to present a model that extends and
compliments current mathematical models and allows for a theoretical testing of hypotheses put forth in
recent experimental work that is difficult to test in vivo or in clinical settings.
The most prominent consideration in the development of this model, that differs significantly from
previous work, has been the explicit inclusion of osteocyte cell populations, and the effects of osteocyte
signaling on bone turnover during targeted bone remodeling. First, in contrast to previous mathematical
models that required perturbation away from a positive steady state to begin a remodeling cycle, our
model allows for a more natural (physiological) initiation of a cycle of targeted bone remodeling. Second,
the steady state values for forming or resorbing bone cells is in better agreement with what is physiologi-
cally expected, since the presence of mature osteoclasts and osteoblasts is not expected in the absence of
a remodeling BMU. Finally, the approach taken here allows for a natural representation of the action of
sclerostin which inhibits Wnt signaling and pre-osteoblast proliferation, and may also promote osteoclast
activity.
We have used, following [28], the steady state bone volume as a control to examine aspects of tar-
geted bone remodeling such as osteocyte RANKL expression, initiation of targeted bone remodeling with
osteocyte apoptosis, and the role of sclerostin that are of current interest to the larger bone remodel-
ing community. We have shown that this model is appropriate for determining whether osteocyte or
pre-osteoblast RANKL expression plays the more prominent role in osteoclastogenesis for adult bone
remodeling. Furthermore, we have applied this model to study the effects of an anti-sclerostin drug, such
as an anti-sclerostin monoclonal antibody described in [53], on bone turnover.
One important feature of bone remodeling that is beyond the scope of the model presented in this work
is spatial bone remodeling. We point out that the main thrust of spatially explicit mathematical models
of bone remodeling have been spatial extensions of purely temporal models, see e.g., [1,15]. That is, the
ordinary differential equations used to model local bone remodeling are extended to partial differential
equations.
However, a different framework for spatial extensions based on level set methods (LSM) is also possible,
see e.g., [20,55]. The models used in [20,55] did not include the role of osteocytes, or differentiate between
precursor cells and active osteoblasts and osteoclasts. Nonetheless the works [20, 55] provide a proof of
concept for a new spatial representation of bone remodeling, and demonstrate the sort of pitfalls that
might occur when spatially extending the model to scales of interest for bone marrow biopsy cores. Quite
importantly, we did not see a change in the local behavior based on embedding into the LSM spatial
representation; in fact local behavior translated into spatial behavior well.
Another feature, somewhat related to spatial behavior and not considered in this work are the me-
chanical mechanisms involved in the initiation and regulation of bone remodeling. This is primarily due
to the fact that this work considers local remodeling at the scale of an individual BMU but without
treating the problem of BMU steering.
Decades of experimental studies on bone remodeling reveal a dynamic process that is sensitive to
multiple local and humoral factors. In silico modeling based on this accumulated knowledge offers a
means to assess systematically the effects of perturbing individual parts of the system at a rate that
cannot be matched by experiments conducted in vivo. As such, model-based predictions are particularly
useful for the development of new treatments for bone disorders. This is somewhat illustrated by results
from our model, which underscore the decisive influence of osteocytes and the potential for sclerostin-
targeted treatments to reduce bone loss in pathologic conditions ranging from osteoporosis to osteolytic
cancers.
It has been noted that dysfunctional or apoptotic osteocytes contribute to post-menopausal, steroid-,
and immobilization-induced osteoporosis (reviewed by [56]). High circulating levels of sclerostin have been
associated with osteoporosis, Paget’s disease, and metastatic bone disease [57,58]. Intriguingly, sclerostin
has also been found to be expressed by malignant plasma cells in multiple myeloma [59]. Agents targeting
10
sclerostin are under development, representing a novel therapeutic strategy compared with such currently
available options as the bisphosphonates which directly disrupt osteoclast function. Disorders of bone
remodeling affect millions of individuals and are responsible for considerable morbidity and mortality,
resulting billions of dollars in healthcare costs each year. Given the complexity of the cellular and
biochemical processes which mediate bone remodeling, the availability of a mathematical model which
can capture all of these elements is an exceedingly useful tool for understanding bone remodeling in
the setting of disease. Our model, which, to our knowledge, is the first to incorporate osteocytes and
sclerostin, can be used to answer questions regarding the relative impact of cell type-specific activity. Not
only can the effects of existing therapeutic agents be modeled, but this model could be used to explore
the effects of modulating the activity of new targets thus providing rationale for new drug development.
Furthermore, this model could be extended to multiple myeloma by the incorporation of plasma cells and
the resulting interactions between the bone and stromal cells.
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Figure 1. Interactions between bone cell populations.
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Figure 2. System of ordinary differential equations constructed, using the biochemical systems analysis
formalism [32–36], to model osteocyte-induced targeted bone remodeling.
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Figure 3. Dynamics of bone cells during a single event of targeted bone remodeling. The dynamics of
osteocyte (a), pre-osteoblast (b), osteoblast (c), and osteoclast (d) populations during an event of
targeted bone remodeling.
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Figure 4. Dynamics of bone volume during a single event of targeted bone remodeling.
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Figure 5. The steady state bone volume, zss, as a simultaneous function of the effectiveness of
osteocyte paracrine signaling on stromal cell differentiation, g21, and pre-osteoblast autocrine signaling
for pre-osteoblast proliferation, g32.
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Figure 6. The steady state bone volume, zss, computed as a function of the effectiveness of osteocyte
paracrine signaling on stromal cell differentiation, g21, with all other parameters held at baseline values.
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Figure 7. The steady state bone volume, zss, computed as a function of the effectiveness of
pre-osteoblast autocrine signaling for pre-osteoblast proliferation, g32, with all other parameters held at
baseline values.
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Figure 8. We simulate the loss of bone mass associated with over resorption in conjunction with a
bone degenerative disease, modeled by a slight increase in the value of α4 with all other parameters set
to the baseline values listed in table 2.
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Figure 9. This figure shows simulation results of treating pathological bone remodeling, as simulated
in figure 5, via the addition of an anti-sclerostin drug. This results in a dose-dependent increase in bone
mass. Treatment with an anti-sclerostin drug is modeled by modifying the appropriate signaling
mechanisms, that is, by modifying the appropriate exponents g22 and g44 in the power law
approximation.
22
Table 1. Definitions of Symbols Used in the Paper
Symbol Definition
S Number of osteocytes at a given time t
P Number of pre-osteoblasts at a given time t
B Number of osteoblasts at a given time t
C Number of osteoclasts at a given time t
z Bone volume at a given time t
α1 Osteoblast embedding rate
α2 Differentiation rate of pre-osteoblast precursors
α3 Pre-osteoblast proliferation rate
β1 Differentiation rate of pre-osteoblasts
δ Apoptosis of pre-osteoblasts
β2 Osteoblast apoptosis
α4 Differentiation rate of osteoclast precursors
KS Critical value of osteocyte population
k1 Bone resorption rate
k2 Bone formation rate
g31 Effectiveness of osteoblast autocrine signaling
g21 Effectiveness of osteocyte paracrine signaling of pre-osteoblasts
g22 Effectiveness of sclerostin regulation of osteoblastogenesis
g32 Effectiveness of pre-osteoblast autocrine signaling
g41 Effectiveness of osteocyte paracrine signaling of osteoclasts
g42 Effectiveness of pre-osteoblast paracrine signaling of osteoclasts
g43 Effectiveness of osteoblast paracrine signaling of osteoclasts
g44 Effectiveness of sclerostin regulation of osteoclastogenesis
f12 Effectiveness of pre-osteoblast paracrine signaling of osteoblasts
f14 Effectiveness of osteoclast paracrine signaling of osteoblasts
f23 Effectiveness of osteoblast autocrine signaling for apoptosis
f34 Effectiveness of osteoclast autocrine signaling for apoptosis
θ(·) Heaviside function
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Table 2. Parameter Values
Parameter Value Units
α1 0.5 per day
α2 0.1 per day
α3 0.1 per day
β1 0.1 per day
δ 0.1 per day
β2 0.1 per day
α4 0.1 per day
KS 200 number of cells
k1 0.7 % volume per day
k2 0.015445 % volume per day
g31 1 dimensionless
g21 2 dimensionless
g22 1 dimensionless
g32 1 dimensionless
g41 1 dimensionless
g42 1 dimensionless
g43 -1 dimensionless
g44 1 dimensionless
f12 1 dimensionless
f14 1 dimensionless
f23 1 dimensionless
f34 1 dimensionless
ε 1 number cells
Table 3. Effectiveness of RANKL Expression.
g41 g42
1
0.22
0.24
0.26
0.28
0.3
0.6
0.62
0.82
0.84
1.14
1.24
1.34
1.42
1.66
1
1.84
1.82
1.8
1.78
1.76
1.44
1.42
1.2
1.18
0.84
0.72
0.6
0.5
0.18
Values of the effectiveness of RANKL expression by osteocytes (g41), and pre-osteoblasts (g42)
corresponding to normal, targeted, bone remodeling.
